Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | TOP1 | P11387 | 2/20 | 0.41 |
| ▸ | TOP2A | P11388 | 1/20 | 0.41 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.41 |
| ▸ | SNCA | P37840 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.40 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2092311 | 0.83 | RAB9A (0.65) | NPC1RAB9AKMT2ALMNAKDM4E | |
| SCHEMBL1136776 | 0.82 | PKM (0.54) | NPC1RAB9AKMT2ALMNAKDM4E | |
| SCHEMBL27761090 | 0.82 | ALDH1A1 (0.57) | NPC1RAB9AKMT2ALMNAKDM4E | |
| SCHEMBL4351601 | 0.82 | MAOA (0.59) | NPC1RAB9AKMT2ALMNAKDM4E | |
| SCHEMBL5172599 | 0.80 | KMT2A (0.68) | NPC1RAB9AKMT2ALMNAHSD17B10 | |
| SCHEMBL22279637 | 0.79 | TNIK (0.52) | KMT2ALMNAKDM4EEPHX2SMN1; SMN2 | |
| SCHEMBL15790439 | 0.78 | RARA (0.51) | NPC1RAB9AKMT2AHSD17B10TP53 | |
| SCHEMBL17802331 | 0.78 | RAB9A (0.46) | NPC1RAB9AKMT2ALMNAHSD17B10 | |
| SCHEMBL13862071 | 0.78 | FFAR4 (0.50) | NPC1RAB9AKMT2ALMNAKDM4E | |
| SCHEMBL1137180 | 0.78 | MAOB (0.51) | NPC1RAB9AKMT2ALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4339197-A1 | NOVEL UREA DERIVATIVE COMPOUND AS RON INHIBITOR | Lg Chem, Ltd. (KR) | 2024-03-20 | — | — | EP | disclosed |
| EP-4339196-A1 | NOVEL UREA DERIVATIVE COMPOUND AS RON INHIBITOR | LG Chem, Ltd. (KR) | 2024-03-20 | — | — | EP | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| WO-2022270980-A1 | NOVEL UREA DERIVATIVE COMPOUND AS RON INHIBITOR | 주식회사 엘지화학 | 2022-12-29 | — | — | WO | disclosed |
| WO-2022270979-A1 | NOVEL UREA DERIVATIVE COMPOUND AS RON INHIBITOR | 주식회사 엘지화학 | 2022-12-29 | — | — | WO | disclosed |
| US-8445509-B2 | Fused heterocyclic derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-21 | — | — | US | disclosed |
| EP-1702919-B1 | NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE | MSD KK (JP) | 2012-05-30 | — | — | EP | disclosed |
| EP-2374806-A1 | OXAZOLIDINON-QUINOLONe HYBRIDes and intermediates for their preparation | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2011-10-12 | — | — | EP | disclosed |
| EP-2336123-A2 | HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR | Neopharm Co., Ltd. (KR) | 2011-06-22 | — | — | EP | disclosed |
| US-7728025-B2 | 2-heteroaryl-substituted benzimidazole derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20080070928-A1 | Novel 2-Heteroaryl-Substituted Benzimidazole Derivative | MSD K.K. (JP) | 2008-03-20 | — | — | US | disclosed |
| WO-2007071840-A2 | COMPOUNDS BASED ON FOUR AROMATIC RINGS, PREPARATION AND USES THEREOF | CEREP (FR) | 2007-06-28 | — | — | WO | disclosed |
| EP-1702919-A1 | NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | NPC1 348/4885RAB9A 3477/4885KMT2A 4530/4885 |
| US-20080070928-A1 | Novel 2-Heteroaryl-Substituted Benzimidazole Derivative | GCK, GCKR, HK1 | NPC1 748/4885RAB9A 4133/4885KMT2A 1946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.